Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Jun
22
2018
Opioids Have Our Attention Mintz
Aug
21
2018
California Supreme Court Ends Glyphosate Debate, for the Time Being Mintz
Jan
15
2022
Building on the Success of Medicare-Medicaid Plans, CMS Proposes Modifications for D-SNPs Mintz
Jan
24
2022
CMS Proposes Changes to Part D Regulations: Pharmacy Price Concessions Mintz
Dec
11
2013
Energy and Environmental Law Update - December 9, 2013 Mintz
Jan
6
2014
Energy & Environmental Law Update - Week of January 6, 2013 Mintz
Feb
17
2022
D. Del. Says ANDA Specification Trumps All Else in Infringement Analysis Mintz
Mar
26
2014
Energy and Environmental Law Update - March 24, 2014 Mintz
Apr
15
2014
Energy and Environmental Law Update - April 14, 2014 Mintz
Apr
26
2022
Medicaid Best Price 101: A Review of Medicaid Best Price Policy and New CMS Guidance on Medicaid Best Price Reporting for Value Based Purchasing Arrangements Mintz
May
3
2022
Massachusetts for ARPA-H Mintz
Jan
25
2019
CMS Addresses Drug Manufacturer Coupons in Proposed 2020 Payment Notice Mintz
Aug
18
2014
CMS Re-Opens Open Payments System Mintz
Jun
30
2022
PBMs Continue to Draw Federal Scrutiny: PBM Transparency Act of 2022 Mintz
Aug
25
2014
FDA Notifies Congress of Framework for Long-Awaited Guidance on Laboratory Developed Tests and Issues Final Guidance on Companion Diagnostics Mintz
Apr
1
2019
FDA Silent on CBD Regulation at Cosmetics Conference, But Legislation May Be Imminent Mintz
Sep
7
2022
FDA Announces Review of Opioid Prescribing Regulations and Framework for Preventing Overdose-Related Deaths Mintz
Sep
28
2022
MintzRx — Digital Health Update: Federal Government Shows Growing Enforcement Interest in Online Prescribing of Controlled Substances Mintz
Oct
17
2022
California's New Law Prohibits Discrimination Against Employees For Off-The-Clock Use Of Cannabis Mintz
Jul
29
2019
ML Strategies Health Care Preview - Week of July 29, 2019 Mintz
Aug
14
2019
Congress Looking to Streamline CBD Drug Research Mintz
May
28
2015
GMOs at the Ballot Box: the Drama Continues Mintz
Jun
4
2015
The Federal Circuit’s First Foray into the BPCIA: “A Pulitzer Prize for Complexity”? Mintz
Mar
16
2023
AG Garland Signals That Department of Justice's Cannabis Policy Will Be "Very Close" To Cole Memorandum Mintz
Oct
10
2019
Collateral Estoppel Does Not Attach To PTAB Invalidity Determination Pending Appeal Mintz
Jun
9
2023
FTC and DOJ Antitrust Memorialize Joint Workshop on the Future of Antitrust Enforcement in the Pharmaceutical Industry Mintz
Dec
9
2019
HHS HIV Drug Lawsuit: Setting Precedent for Other High Priced Medications or Government Collaborations? Mintz
Jun
20
2023
Effective July 1, Florida Will Prohibit Offshore Storage of Health Records and Require Additional Ownership Disclosures Mintz
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins